T ricuspid regurgitation (TR) is a frequent valvular heart disease, with 1.6 million patients in the United States suffering from severe symptomatic TR. 1, 2 TR most frequently occurs secondary to annular dilation and leaflet tethering because of right ventricular (RV) dilation. 3 The latter is often caused by pressure or volume overload, which is mainly driven by left-sided heart pathologies such as heart failure, with preserved or reduced left ventricular (LV) function and aortic or mitral valve disease. 4 However, TR appears to be more than an innocent bystander because it is related to high morbidity and poor outcomes. 5 Dedicated treatment options for severe TR are scarce: Medical therapy is mostly restricted to diuretics and surgical repair because isolated TR is reserved for selected patients at low surgical risk and with severe symptoms despite optimal medical treatment. 1, 2 The benefit of isolated surgery on prognosis and morbidity is not clear, and perioperative mortality is high. 6 The prognostic impact of additional surgical tricuspid valve repair in patients with concomitant severe TR undergoing left-sided open-heart surgery is also not clear. 7, 8 Thus, despite the high incidence of relevant symptomatic TR, pharmacological and surgical treatment options are limited. Hence, clinical need exists for the development of transcatheter strategies to address symptomatic severe TR. Currently, numerous catheter-based devices are in preclinical and clinical testing. [9] [10] [11] None of these dedicated interventional devices is available for regular clinical use yet. Because of experience regarding complex steering maneuvers with the guiding catheter from >40 000 MitraClip procedures for mitral regurgitation, a clipping approach for the treatment of TR stands to reason. Consequently, the interventional edge-to-edge repair with the MitraClip system had already been successfully applied in isolated patients with TR. 12 We herein report procedural safety and efficacy, as well as functional outcomes of 64 patients treated with the MitraClip device for severe TR.
METHODS Patients
Patients with severe TR were recruited from 10 international centers ( Figure 1 ). All patients were considered unsuitable for surgery, and the interventional approach with the MitraClip system was offered as compassionate use. We included consecutive patients with symptomatic moderate to massive TR on optimal medical treatment.
Patients with a systolic pulmonary arterial pressure >60 mm Hg were excluded. A severe coaptation defect (>2 cm) of the tricuspid leaflets was also an exclusion criterion (n=10). Further, 3 patients who refused the interventional procedure were excluded. Patients were subdivided according to concomitant mitral MitraClip procedure or TR procedure alone. Follow-up visits were scheduled before discharge and, if possible, at 30 days after the procedure. Echocardiographic evaluation of TR grade and assessment of clinical symptoms and exercise capacity, measured with the 6-minute walking distance test, formed part of the follow-up evaluation.
The study was approved by the Ethics Committee of the University of Bonn and was conducted in concordance with the Declaration of Helsinki. All patients had to provide written informed consent. Data were collected using standardized case report forms, which were analyzed at the Heart Center of the University of Bonn.
Interventional Edge-to-Edge Repair of TR
The MitraClip system has been described in detail previously. 13 Procedural success was defined as safe clip implantation without partial leaflet detachment or device migration and reduction of TR of ≥1 grade without creating a tricuspid stenosis. An acceptable gradient after clipping was determined as ≤3 mm Hg.
After clip placement, the acute effect on global TR was quantified. It was left to the discretion of the treating physician if a second or third clip had to be used. More than 1 clip was used if satisfactory reduction of TR was not achieved after implantation of the first clip. In addition, a second implantation site had to be identified where successful grasping was expected ( Figure 2) .
The procedure was performed under general anesthesia with interventional guidance by 2-and 3-dimensional transesophageal echocardiography () and fluoroscopy in all cases.
Clinical Perspective
What Is New?
• Treatment of tricuspid regurgitation using a percutaneous approach with the MitraClip system is safe, feasible, and efficient in reducing tricuspid regurgitation in preselected patients with tricuspid regurgitation.
• This new technique for interventional treatment of tricuspid regurgitation may lead to improved symptoms and performance.
• Anatomic and echocardiographic feasibility criteria are not well defined, and further research is needed to determine which patients might benefit from this technique.
What Are the Clinical Implications?
• Our data reveal a favorable safety profile of the tricuspid clipping procedure with no observed periprocedural serious adverse events.
• The majority of the procedures were performed through transfemoral access, and most clips were placed at the anteroseptal commissure.
• A combination of different approaches such as interventional annuloplasty and the clip technique may lead to superior procedural results and pronounced clinical benefit especially in patients with functional TR and dilated tricuspid annulus.
Unfractionated heparin was administered after sheath insertion aiming to reach an activated clotting time of 250 to 350 seconds throughout the procedure. The 24 French sheath was introduced in the right atrium by the jugular (11%) or femoral (89%) vein. Three-dimensional transesophageal echocardiography confirmed correct clip orientation in relation to the tricuspid valve, with the clip arms perpendicularly aligned to the targeted commissure. Transgastric views aided clip orientation and localization in the designated commissure. Leaflet grasping was documented using mid-to deep-transesophageal 4-chamber views corresponding to long-axis and transgastric views. Finally, the system was retracted, and the puncture side was closed using a so-called "Z-suture." 
Transjugular Approach
After puncture of the right internal jugular vein, the steerable guide system was introduced by the superior vena cava into the right atrium. Owing to the approach from the internal jugular vein, the clip catheter was inserted in the sheath after 90-degree clockwise rotation. Anterior rotation of the steerable sheath directs the clip toward the anteroseptal commissure of the valve; navigation of the system posterior and septal can be achieved with the "+/-" knob. The "a/p" knob allows to some extent for optimization of the clip orientation toward the tricuspid leaflets.
Transfemoral Approach
In the majority of patients, the guide catheter was introduced in the right atrium by the inferior vena cava after puncture of the right femoral vein. If unstraddled, with the clip unsheathed out of the guide, a 3/4 posterior turn of the guide induces a steeper angle of the clip. Hereby, the clip may move anterior or posterior, which has to be compensated by turning the "p" knob, which directs the clip in a more septal position. The "a/p"knobs allow for directing the clip anterior/posterior (a knob) or septal (p knob). The "+" knob navigates the clip toward the posteroseptal commissure and directs it in a steeper angle toward the valve. The "-" knob moves the clip toward the anteroseptal commissure, and the clip angle becomes shallower. Furthermore, the "-" knob elevates the clip, whereas the "+" knob leads to a movement toward the tricuspid valve (Figure 3 ). The use of the "M" and "L" knobs are neither necessary nor effective.
Echocardiographic Assessment
The echocardiographic studies (baseline, discharge, 30 days) were carried out and interpreted in the participating centers; no core laboratory analysis of the obtained echocardiographic data was performed. For determination of feasibility and procedural planning, all patients underwent transthoracic and Figure 3 . Illustration of the steering maneuvers using a transfemoral access.
A, "Short-axis" view: Turning of the a knob directs the clip anterior or posterior (red arrows). B, Transgastric view: Turning of the a knob directs the clip anterior/posterior (red arrows); the p knob directs the device septal/lateral (yellow arrows), "Shortaxis" (C) and transgastric (D) views: The "+" knob navigates the clip toward the posteroseptal commissure and directs it in a steeper angle toward the valve (green arrow). The "-" knob moves the clip toward the anteroseptal commissure, and the clip angle becomes more shallow (blue arrow). The "-" knob elevates the clip, whereas the "+" knob leads to a movement toward the tricuspid valve.*MitraClip in tricuspid position. transesophageal echocardiography. Transgastric views were used to visualize the tricuspid valve "en-face" for determination of jet origin and coaptation deficits. If a pacemaker lead was present, then special care was taken to visualize jet origin and rule out that the pacemaker lead was the relevant reason for TR by tethering a leaflet to the annulus. Those patients were excluded from a tricuspid clipping treatment approach. However, in the patients screened for tricuspid clip therapy, a pacemaker lead was never found to be the reason for TR. Degenerative TR was diagnosed if a prolapsing or flail tricuspid valve or leaflet could be visualized by echocardiography. A tricuspid prolapse was defined as a midsystolic leaflet displacement beyond the annular plane, whereas a tricuspid flail was identified when a free leaflet edge was reversed in the right atrium (eg, as a consequence of ruptured chordae). If these degenerative causes were ruled out and only tricuspid annular dilatation and apical displacement of the tricuspid leaflets with resulting increased coaptation distance were found, then functional TR was diagnosed. If aspects of both etiologies were present, then TR etiology was defined as "mixed." The severity of TR was graded in 4 stages: mild, moderate, severe, and massive. 1, 2, 15 Echocardiographic assessment before, during, and after the procedure was done following current recommendations and guidelines with determination of vena contracta (VC) diameter, effective regurgitant orifice area (EROA), and regurgitant volume (RegVol) estimated with the proximal isovelocity surface area (PISA) method. 15 VC diameter was determined from apical 4-chamber view using 2-dimensional color Doppler. A VC width of ≥7 mm indicated a severe TR. TR PISA was also derived from 2-dimensional color Doppler data obtained on the apical 4-chamber view. The PISA radius was measured at midsystole with the Nyquist limit set to 15 to 40 cm/s. EROA and RegVol were derived from PISA measurements, and the velocity time integral of the TR was calculated using the continuous-wave Doppler data of the regurgitant jet. An EROA of ≥0.4 cm 2 or a RegVol of ≥45 mL/beat defined severe TR. 15 After tricuspid clipping, the EROA and RegVol were calculated separately for each regurgitant jet. The measured EROAs and volumes were summed up to a total EROA and RegVol. Each VC of the regurgitant jets was assessed in the apical 4-chamber view at end systole; if multiple VC jets were present, then their diameters were summed up ( Figure 4) . 16 For the determination of tricuspid geometry and dimensions and characterization of leaflet pathophysiology, tenting distances and areas as well as annular septo-lateral diameters were measured. These measurements were undertaken in transthoracic apical 4-chamber view, with special caution to visualize the RV and tricuspid annulus.
The triangular zone among the tricuspid annulus, the leaflets, and the coaptation point was defined as the tenting area. Tenting distance was defined as the distance between coaptation point of the tricuspid leaflets and the tricuspid annular plane at midsystole. Septo-lateral diameters were measured in end diastole on the apical 4-chamber view as the distance from the lateral to septal tricuspid annulus. It is important to note that a diastolic tricuspid annular diameter of ˃40 mm is a marker indicating severe TR. 15 Tricuspid annular plane systolic excursion was measured on the apical 4-chamber view with the M-mode on the lateral tricuspid annulus and was defined as the maximal excursion at the most lateral aspect of the tricuspid annulus. Tricuspid annular plane systolic excursion <16 mm indicates impaired systolic RV function. RV fractional area change (FAC) was also calculated from apical 4-chamber view. Care was taken to acquire the entire RV, including the apex and the lateral wall in both systole and diastole. FAC was calculated as 100 x end-diastolic area -end-systolic area/end-diastolic area. A FAC <35% defined RV dysfunction. 17 Right atrial (RA) dimensions were measured from the apical 4-chamber views. An RA area of ˃18 cm 2 was considered enlarged. 15 The inferior vena cava (IVC) diameters were obtained from subcostal views and measured proximal to the entrance of hepatic veins. When the IVC diameter measured ˃2 cm, the IVC was judged to be dilated.
Statistics
Continuous and categorical variables are reported as mean with standard deviations and percentages, respectively. Statistical testing was done with the paired t test for continuous variables. The Friedman test was used for categorical variables. A P-value <0.05 was considered statistically significant. Comparisons between the groups were performed using χ 2 -or Kruskal-Wallis test. The presented data are derived from paired analyses. Intraclass correlation coefficients for absolute agreement was used for the assessment of method agreement, with good agreement defined as >0.80. For the assessment of intraobserver variability, 20 randomly chosen patients were analyzed by the same investigator twice and by a second investigator, who was blinded to the results of the first investigator, to determine interobserver variability. Mean values and standard deviations between the measurements were obtained, and absolute agreement among the observation was calculated using intraclass correlation coefficients analysis.
RESULTS

Patients and Baseline Characteristics
Patients (n=64, logistic EuroSCORE [European System for Cardiac Operative Risk Evaluation] 27.8±16.7%, Society of Throacic Surgeons mortality score 4.7±4.6%) deemed inappropriate candidates for open heart surgery by the local heart teams with symptomatic moderate to massive TR were treated with transcatheter edge-to-edge repair using the MitraClip system as a compassionate use.
Mean follow-up time was 14±18 days (7-45 days) after the procedure (Figure 1) . Twenty-two patients were concomitantly treated for mitral regurgitation with the MitraClip device as a combined procedure. Mean age was 76.6±9.6 years, 45% were male, and 93% of the patients presented with NYHA class III-IV symptoms. A relevant number of patients had a history of cardiac surgery (40%) or percutaneous intervention (39%) mostly because of valve or coronary disease (Table 1) .
Baseline echocardiography showed impaired LV ejection fraction (EF) <50% in 82% of patients (average EF: 46.9±13.9%), an impaired RV function with tricuspid annular plane systolic excursion <16 mm and RV FAC <35% in 62% of patients (average tricuspid annular plane systolic excursion: 16.9±5.8 mm, average RV FAC 37.1±13.1%), and only moderately increased systolic pulmonary arterial pressure (42.5±15 mm Hg). All patients with pulmonary arterial hypertension were in group 2 (2013 Nice classification), and none of the patients had precapillary pulmonary hypertension in our study cohort. 18 Functional TR was present in 88%, and the other patients presented with degenerative (8%) or mixed (4%) etiologies, respectively. TR grade was severe or massive in 88% of the cases, which was evidenced by various established (semiquantitative) echocardiographic parameters. All echocardiographic findings regarding TR severity had good reproducibility as shown by absolute intra-and interclass agreement with all correlation coefficients ranging >0.8 (online-only Data Supplement Table I ). Concomitant moderate-tosevere and severe mitral regurgitation was diagnosed in 24 patients; 22 of these individuals underwent a combined clipping procedure of the tricuspid and mitral valves ( Table 2) .
Echocardiographic Procedural Guidance and Procedural Outcomes
A tricuspid MitraClip was successfully placed in 97% of cases. One clip was used in 48% of patients, 42% of patients received 2 to 4 clips, 3% of patients did not receive a clip, and for 7% information on the number of used clips was missing or inconclusive; in 78% of patients the clip was implanted in the anteroseptal commissure (Table 3) . Transesophageal echocardiography was used in 100% of patients. It is important to note that transesophageal echocardiography was utilized in some patients (25%) in whom transesophageal echocardiography image quality was not sufficient for safe clip placement or grasping. Intracardiac echocardiography was used in 1 patient. A significant reduction occurred in severe/massive TR at follow-up compared 6MWT indicates 6-minute walking test; ACE, angiotensin converting enzyme; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; GOT, glutamate oxaloacetate transaminase; GPT, glutamate pyruvate transaminase; NT pro-BNP, N terminal probrain natriuretic peptide; NYHA, New York Heart Association; MR, mitral regurgitation; PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation; TR, tricuspid regurgitation; and yGT, gamma glutamyl transferase. Figure 6 ). The tricuspid annular septo-lateral diameter was also reduced after clipping (41.2±10.6 mm versus 35.7±16.2 mm; P=0.04). RA volume and IVC diameters as well as RV functional parameters were not relevantly changed, as assessed by in-hospital echocardiography (P>0.05), which might be because of the small sample size and the short follow-up period after the procedure. LV ejection fraction was mildly impaired at baseline and significantly improved after the procedure (46.6±13.7% versus 48.3±14.1%; P=0.03), and noninvasive measured systolic pulmonary arterial pressure values were elevated at baseline and significantly decreased after the procedure (44.1±15.4 mm Hg versus 40.4±12.7 mm Hg; P=0.02). 
Clinical Symptoms at Follow-Up
After clip placement, 63% of the patients remained in NYHA class III, and none was in NYHA class IV, as opposed to 93% in NYHA classes III and IV before the intervention (Tables 2 and 4 , Figure 7 ). Blood pressure and heart rates were not statistically different when comparing baseline, postclip, and follow-up measurements (heart rate: 80±20 versus 76±18 versus 71±10 bpm; P=0.07; systolic blood pressure: 117±16 versus 113±13 versus 117±14 mm Hg; P=0.1; diastolic blood pressure: 66±9 versus 67±12 versus 68±7 mm Hg; P=0.1). The baseline exercise capacity as assessed by 6-minute walking test significantly improved 30 days after the procedure (177.4±103.0 versus 193.5±115.9 m; P=0.007) in the 21 patients completing both before and after procedure testing (Table 4) . However, no change occurred in the plasma NT-proBNP (N-Terminal Pro-B-Type natriuretic peptide) level (P=0.9). Prescribed cardiac medication was not changed in the majority of patients during follow-up time. In 15 patients, diuretic doses were reduced. No patient required higher dosages of diuretics.
Intraprocedural and In-Hospital Safety Data
No intraprocedural deaths or emergent conversions to open-heart surgery occurred. No other serious adverse events, including stroke, myocardial infarction, or pericardial effusion, were reported. No device migration occurred. In-hospital mortality was 5% (Table 3) . One of the patients died on day 5 after the intervention because of acute cardiogenic shock, another patient died most possibly because of a systemic inflammatory response syndrome, and a further patient with known severe renal dysfunction died because of hyperkalemia and associated arrhythmia.
Patients With TR Clipping and Concomitant MitraClip Treatment of Mitral Regurgitation
Because concomitant treatment of the mitral valve might have influenced LV and RV function, tricuspid valve performance and clinical outcome, we separately analyzed the 22 patients who underwent a combined procedure with both TR clipping and MitraClip treatment for mitral regurgitation (online-only Data Supplement Table II) . Patients undergoing a combined procedure presented with more impaired LV function (P=0.002) and larger LV volumes (P<0.001) compared with patients with TR clipping only. In all of those patients, moderate to severe mitral regurgitation was present (online-only Data Supplement Table III ). Patients undergoing combined mitral and tricuspid clipping had higher creatinine (1.7±0.8 mg/dL versus 1.3±0.6 mg/dL; P=0.04) and NT-proBNP (N-Terminal Pro-B-Type natriuretic peptide) serum levels (8976.7±6494.1 ng/dL versus 3894.9±5039.7 ng/dL; P=0.03) compared with patients undergoing tricuspid clipping alone. They presented in higher NYHA classes (P=0.03), were more likely to have a history of previous percutaneous coronary interventions (P=0.03), and suffered more often from concomitant aortic valve regurgitation (P=0.03). Furthermore, TR severity grade was significantly different (P=0.03), with more patients presenting with severe (68% versus 52%) and fewer patients with massive TR (18% versus 36%). However, all semiquantitative parameters were similar between both groups of patients (P>0.05). The other demographic and clinical baseline character- 
DISCUSSION
In this multicenter study, we observed that using the MitraClip system for treatment of TR in selected patients unsuitable for surgery was safe and had no periprocedural mortality. We also demonstrated feasibility and efficacy of this approach in reducing TR in this patient population.
Functional TR is the most frequent etiology, which is characterized by annular dilatation and tenting of tricuspid leaflets causing malcoaptation and regurgitation. Organic causes of TR are less frequent and characterized by abnormal or damaged leaflets.
TR and possible interventional treatment approaches have gained more and more attention for several reasons: TR causes specific symptoms, such as edema, ascites, fatigue, shortness of breath, and liver and renal failure, which can be addressed only partially by medical therapy, and further specific treatment options for severe symptomatic TR are limited. 4 TR is associated with poor outcome as an isolated disease as well as when combined with left heart pathologies. 19 It is important to note that the presence of TR in individuals who are treated for left-side heart pathologies is associated with a poor prognosis. 7, [19] [20] [21] Recent evidence suggests that patients undergoing a MitraClip procedure for mitral regurgitation benefit less if concomitant TR is present.
22,23
Herein, we report on the largest cohort treated for symptomatic TR using a percutaneous catheter-based edge-to-edge repair approach. Other catheter-based interventional techniques approach TR by annuloplasty, bicuspidalization of the tricuspid valve, or closing the central leakage. However, all of those dedicated devices are in the early stages of clinical development and investigation and have only been used in a limited number of patients so far. No prospective studies on this topic have been published, but safety and feasibility have been demonstrated in few selected patients. 11, 24, 25 In the present study, TR was significantly reduced as evidenced by echocardiography, comparable to surgical data. 26 In a cohort of 216 patients undergoing surgical tricuspid annuloplasty, Fukuda and colleagues 26 noted persistent severe TR in 10% of patients in the early postoperative period, which compares well with our results. In our study, 13% of patients had severe TR early after interventional TR repair despite a significantly lower inhospital mortality compared to their findings (5% versus 30%). 3, 26 However, even if TR is improved after a clipping procedure, it does not guarantee improvement in RV function because the RV is now exposed to a higher afterload.
In addition to our limited sample size and follow-up time, this finding may account for the absent changes in RV functional parameters in our study, although TR was reduced, IVC diameters improved, and the RA became smaller after clipping.
Bertrand et al 27 described a similar observation in their study of 45 consecutive patients undergoing tricuspid annuloplasty. They found amelioration in RV function, as measured by RV FAC, only in patients with moderate TR at baseline and even deterioration of RV function in patients with severe TR. Moderate TR was present in only 12% of our patients, in contrast to 71% in the cited study, which might have influenced our results on RV function.
In our study, the preferred access route was transfemoral, and no navigation or angle problems were encountered using this access. After preprocedural echocardiographic evaluation, most clips were placed at the anteroseptal commissure, which may be because of the easy access with the transcatheter device and also substantiated by the fact that in most cases tricuspid annular dilation is pronounced at the anteroseptal region. Because the transesophageal 4-chamber and long-axis views easily depict the septal and anterior tricuspid leaflets and the anteroseptal commissure, imaging may favor grasping attempts in the anteroseptal commissure. Vismara and coworkers 28 recently found in an ex-vivo model that grasping of the septal and anterior leaflets allowed for the best postprocedural outcome, with possible reestablishment of physiological-like hemodynam- Figure 7 . Stapled columns diagram of New York Heart Association (NYHA) functional class at baseline and before discharge.
ics. Furthermore, they proved that placing a clip in the anteroposterior commissure did not induce a reduction of TR and had, in some cases, even a deteriorating effect on tricuspid annular geometry and thus on TR. 28 However, the definite location of clip placement was left to the interventionalist in the study at hand.
TR was reduced but not diminished to trace or zero regurgitation in the majority of patients in our current study. It may be speculated that this might necessitate multiple clips. In this study, however, patients treated with ˃2 clips were not left with less regurgitation possibly because these individuals presented with more extensive disease. One could speculate that a larger clip device could be of help, given the frequently large coaptation defects. Although TR was not completely eliminated and in most cases only reduced by 1 grade, improvement in NYHA class was evident for most individuals. This outcome is in line with other reports on catheter-based treatment of TR. [10] [11] [12] 29 Perhaps even a subtle reduction of TR might increase cardiac performance and decrease venous congestion so that physical exercise is facilitated and symptoms are relieved.
A combination of different approaches such as interventional annuloplasty and edge-to-edge repair may lead to superior procedural results and pronounced clinical benefit in patients with functional TR.
Study Limitations
We present data of an observational, exploratory study on feasibility of tricuspid valve clipping. This study is not a randomized trial with core laboratory adjudication and predefined inclusion criteria. Our study comprised no medically treated control group to compare with. In addition, follow-up was limited, and a relevant amount of follow-up data could not be obtained. Therefore, it is currently not known whether the presented treatment modality is able to induce sustained clinical benefit or improve prognosis in this severely diseased patients. This task will be addressed in further studies.
CONCLUSION
Treatment of TR with the MitraClip device seems feasible and safe in this preselected high-risk patient cohort. A reduction of TR may potentially translate into better clinical symptoms and performance. Because anatomic and echocardiographic feasibility criteria are not well defined, further research is needed to determine which patients may benefit most from interventional TR repair.
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